Published in Proc Natl Acad Sci U S A on November 23, 1999
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J (2001) 1.91
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci (2010) 1.78
Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol (2006) 1.77
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol (2007) 1.74
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
CB2 receptors in the brain: role in central immune function. Br J Pharmacol (2007) 1.66
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol (2004) 1.56
Novel cannabinoid receptors. Br J Pharmacol (2007) 1.55
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (2004) 1.51
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2003) 1.50
Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci (2008) 1.48
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med (2009) 1.44
Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl) (2011) 1.44
Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol (2002) 1.41
Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res (2008) 1.39
The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol (2005) 1.38
Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol (2003) 1.37
Endocannabinoid signaling in microglial cells. Neuropharmacology (2008) 1.36
Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol (2001) 1.35
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol (2000) 1.32
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol (2012) 1.31
Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br J Pharmacol (2003) 1.31
Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J (2001) 1.29
Endocannabinoids in liver disease. Hepatology (2011) 1.27
The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol (2007) 1.25
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24
Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat (2009) 1.23
Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology (2005) 1.23
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol (2005) 1.23
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol (2005) 1.20
Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol (2002) 1.17
Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol (2009) 1.15
Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol (2005) 1.14
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol (2008) 1.09
Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci (2007) 1.08
Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol (2004) 1.08
Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem (2009) 1.07
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis (2010) 1.07
Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol (2006) 1.07
Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol (2004) 1.06
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol (2006) 1.05
N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol (2010) 1.04
The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther (2008) 1.03
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca2+ influx. Br J Pharmacol (2003) 1.03
CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol (2003) 1.02
Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) (2012) 1.02
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br J Pharmacol (2012) 1.00
Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem (2008) 1.00
Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol. J Leukoc Biol (2008) 1.00
Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation. Br J Pharmacol (2005) 1.00
Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol (2014) 0.98
The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol (2008) 0.98
CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice. Hypertension (2002) 0.97
Loss of cannabinoid receptor CB1 induces preterm birth. PLoS One (2008) 0.96
Estrogen-related receptor γ controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol. Gut (2012) 0.96
Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol (2007) 0.96
The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther (2010) 0.96
The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther (2009) 0.95
The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem (2007) 0.95
Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol (2005) 0.95
Multiple actions of anandamide on neonatal rat cultured sensory neurones. Br J Pharmacol (2004) 0.94
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol (2006) 0.93
Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol (2003) 0.93
The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol (2005) 0.93
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets (2008) 0.92
N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol (2010) 0.91
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol (2011) 0.91
GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br J Pharmacol (2012) 0.91
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol (2006) 0.90
Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol (2007) 0.90
Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology (2012) 0.89
Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol (2012) 0.89
Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol (2008) 0.89
Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol (2009) 0.88
N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways. Mol Pharmacol (2012) 0.88
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 10.05
K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature (1998) 6.29
Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res (1996) 5.77
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 5.30
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 2.48
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol (1996) 2.21
Cannabinoid pharmacology. Pharmacol Rev (1986) 2.15
Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol (1999) 2.12
Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension (1999) 2.03
Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest (1997) 1.95
A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol (1997) 1.94
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension (1997) 1.75
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol (1996) 1.75
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett (1998) 1.58
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension (1996) 1.46
Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol (1974) 1.40
Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. Br J Pharmacol (1997) 1.38
Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol (1999) 1.37
The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol (1998) 1.34
Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) (1996) 1.29
Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol Sci (1998) 1.20
Stimulus-secretion coupling in vascular endothelial cells. Annu Rev Physiol (1990) 1.18
Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun (1998) 1.18
Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Br J Pharmacol (1999) 1.14
Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med (Berl) (1999) 1.14
Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol (1997) 1.12
Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal (1999) 1.04
Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol (1996) 1.01
A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia (1977) 1.00
Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology (1990) 0.99
Hashish. A simple one-step synthesis of (-)-delta1-tetrahydrocannabinol (THC) from p-mentha-2,8-dien-1-ol and olivetol. J Am Chem Soc (1974) 0.85
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc Natl Acad Sci U S A (1986) 10.41
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
Identification of a family of muscarinic acetylcholine receptor genes. Science (1987) 6.21
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Reduction in the rate of DNA reassociation by sequence divergence. J Mol Biol (1973) 4.94
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A (1983) 4.82
Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones. Biochem J (1971) 4.50
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J (1972) 4.05
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med (1998) 3.75
Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A (1997) 3.59
Corticosteroid therapy of alcoholic hepatitis. Gastroenterology (1978) 3.21
The dynamin-related GTPase, Mgm1p, is an intermembrane space protein required for maintenance of fusion competent mitochondria. J Cell Biol (2000) 3.14
Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. Cell (1987) 3.11
Improved lactose digestion and intolerance among African-American adolescent girls fed a dairy-rich diet. J Am Diet Assoc (2000) 2.94
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron (2001) 2.81
Endothelial apoptosis in Braf-deficient mice. Nat Genet (1997) 2.77
Purification of synaptic vesicles from elasmobranch electric organ and the use of biophysical criteria to demonstrate purity. Biochemistry (1978) 2.62
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Sequence interpretation. Functional annotation of mouse genome sequences. Science (2001) 2.54
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther (2007) 2.53
The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene. Nucleic Acids Res (1986) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol (1989) 2.42
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol (1993) 2.27
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol (1985) 2.19
Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature (1996) 2.17
International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev (2002) 2.15
Sampling variability on percutaneous liver biopsy. Arch Intern Med (1979) 2.12
Cloning of a serotonin transporter affected by antidepressants. Science (1991) 2.12
Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem (1996) 2.11
The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther (2009) 2.08
Role of adenine and guanine nucleotides in the activity and response of adenylate cyclase systems to hormones: evidence for multisite transition states. Adv Cyclic Nucleotide Res (1975) 2.06
Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J (1994) 2.06
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
The molecular basis of muscarinic receptor diversity. Trends Neurosci (1989) 2.04
Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension (1999) 2.03
Mechanisms regulating adipose-tissue pyruvate dehydrogenase. Biochem J (1972) 2.01
Detection of hepatitis A antigen by immunofluorescence. Infect Immun (1977) 2.00
Continuous infusion of pyridostigmine in the management of myasthenic crisis. Crit Care Med (1993) 1.99
Aging and ethanol metabolism. Clin Pharmacol Ther (1977) 1.99
The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development (1994) 1.98
The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res (1987) 1.98
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Evidence favouring the existence of a single adrenergic receptor. Nature (1968) 1.96
Cloned endogenous retroviral sequences from human DNA. Proc Natl Acad Sci U S A (1982) 1.94
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A (1996) 1.94
Chemical and physical characterization of cholinergic synaptic vesicles. Biochemistry (1978) 1.90
Cannabis: pharmacology and toxicology in animals and humans. Addiction (1996) 1.89
Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J (1998) 1.89
Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse (2008) 1.87
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
Brain voltage-sensitive calcium channel subtypes differentiated by omega-conotoxin fraction GVIA. Proc Natl Acad Sci U S A (1986) 1.85
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther (1996) 1.85
Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther (2007) 1.81
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther (2008) 1.80
Biochemistry of neurotransmitter release. Annu Rev Neurosci (1979) 1.78
Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem (2000) 1.78